Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALGS 
Aligos Therapeutics Inc (ALGS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALGS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 21.19% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.66M USD | Price to earnings Ratio - | 1Y Target Price 101.67 |
Price to earnings Ratio - | 1Y Target Price 101.67 | ||
Volume (30-day avg) 168211 | Beta 2.52 | 52 Weeks Range 6.76 - 46.80 | Updated Date 04/1/2025 |
52 Weeks Range 6.76 - 46.80 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -20.94 |
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -3.67 | Actual -13.1 |
Profitability
Profit Margin - | Operating Margin (TTM) -3269.16% |
Management Effectiveness
Return on Assets (TTM) -50.29% | Return on Equity (TTM) -415.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1512207 | Price to Sales(TTM) 11.07 |
Enterprise Value 1512207 | Price to Sales(TTM) 11.07 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 5314310 | Shares Floating 4373872 |
Shares Outstanding 5314310 | Shares Floating 4373872 | ||
Percent Insiders 11.58 | Percent Institutions 34.16 |
Analyst Ratings
Rating 4.33 | Target Price 103.33 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aligos Therapeutics Inc
Company Overview
History and Background
Aligos Therapeutics, Inc. was founded in 2018. It is a biopharmaceutical company focused on developing novel therapies to address liver diseases.
Core Business Areas
- Chronic Hepatitis B (CHB): Developing treatments aimed at achieving a functional cure for CHB.
- NASH: Developing therapies for the treatment of Non-Alcoholic Steatohepatitis.
Leadership and Structure
Lawrence M. Blatt, Ph.D., MBA is the current CEO. The company has a typical structure for a biotech, with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- ALG-010133 (STOPSu2122 molecule): An investigational antisense oligonucleotide designed to reduce hepatitis B surface antigen (HBsAg) levels. Currently in clinical trials. It is difficult to estimate market share at this stage of development, as the drug is not yet approved. Competitors include Gilead Sciences (GILD) and Vir Biotechnology (VIR).
- ALG-020572 (RNAi oligonucleotide): Another investigational agent targeting HBV RNA. Currently in clinical trials. Market share data unavailable and still years from any. Competitors include Roche (RHHBY) and Arrowhead Pharmaceuticals (ARWR).
Market Dynamics
Industry Overview
The liver disease therapeutics market is growing due to increasing prevalence of CHB and NASH. There is a high unmet need for effective therapies.
Positioning
Aligos is positioned as an innovative company focused on developing novel therapies for chronic liver diseases. Competitive advantages include their specific targeting mechanisms and scientific expertise.
Total Addressable Market (TAM)
The global NASH market is projected to reach over $50 billion by 2030. The CHB market is also multi-billion. Aligos is attempting to gain a piece of these significant markets.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Experienced management team
- Strong scientific expertise
- Focus on high unmet medical needs
Weaknesses
- Early-stage pipeline
- High cash burn rate
- Reliance on clinical trial success
- Limited revenue
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other liver diseases
- Positive clinical trial results
- Regulatory approvals for lead candidates
Threats
- Clinical trial failures
- Competition from other companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- GILD
- VIR
- RHHBY
- ARWR
Competitive Landscape
Aligos competes with larger, more established pharmaceutical companies. Their advantage lies in their novel approaches, but they face challenges in terms of resources and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of pipeline expansion and R&D investment.
Future Projections: Future growth depends on the success of clinical trials and potential partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing lead candidates into later-stage clinical trials and exploring strategic alternatives.
Summary
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for liver diseases. While the company possesses innovative approaches and scientific expertise, it faces significant financial challenges. The success of Aligos hinges on positive clinical trial results and strategic partnerships. Its strategic alternative review might mean it doesn't exist as a standalone company in a while.
Similar Companies
ARWR
Arrowhead Pharmaceuticals Inc
ARWR
Arrowhead Pharmaceuticals Inc
BMRN
Biomarin Pharmaceutical Inc
BMRN
Biomarin Pharmaceutical Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aligos Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-10-16 | CEO, President & Chairman of the Board Dr. Lawrence M. Blatt MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.aligos.com |
Full time employees 70 | Website https://www.aligos.com | ||
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.